Terazosin Hydrochloride description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Terazosin Hydrochloride

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

TERAZOSIN HYDROCHLORIDE DESCRIPTION



Terazosin Hydrochloride



CLINICAL PHARMACOLOGY

Pharmacodynamics
A. Benign Prostatic Hyperplasia (BPH)




**


Study 1Figure 1

Terazosin Hydrochloride
23




Terazosin Hydrochloride







Terazosin Hydrochloride






*****B. Hypertension









Pharmacokinetics



INDICATIONS & USAGE




TERAZOSIN HYDROCHLORIDE CONTRAINDICATIONS



WARNINGS

Syncope andFirst-doseEffect
Terazosin hydrochloride capsules, like other alpha-adrenergic blocking agents, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy. A similar effect can be anticipated if therapy is interrupted for several days and then restarted. Syncope has also been reported with other alpha-adrenergic blocking agents in association with rapid dosage increases or the introduction of another antihypertensive drug. Syncope is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by about of severe supraventricular tachycardia with heart rates of120-160 beats per minute. Additionally, the possibility of the contribution of hemodilution to the symptoms of postural hypotension should be considered.
To decrease the likelihood of syncope or excessive hypotension, treatment should always be initiated witha1 mg dose of terazosin, given at bedtime. The 2mg, 5mg and 10 mg capsules are not indicated as initial therapy. Dosage should then be increased slowly, according to recommendations in the Dosage and Administration section and additional antihypertensive agents should be added with caution. The patient should be cautioned to avoid situations, such as driving or hazardous tasks, where injury could result should syncope occur during initiation of therapy.


CLINICAL PHARMACOLOGY

If syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary. There is evidence that the orthostatic effect of terazosin is greater, even in chronic use, shortly after dosing. The risk of the events is greatest during the initial seven days of treatment, but continues at all time intervals.

PRECAUTIONS

PRECAUTIONS

General
Prostatic Cancer


Intraoperative Floppy Iris Syndrome (IFIS)

Orthostatic Hypotension
WARNINGS

INFORMATION FOR PATIENTS

(see Patient Package Insert):




LABORATORY TESTS



DRUG INTERACTIONS



Use with Other Drugs:
DOSAGE AND ADMINISTRATION

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY






PREGNANCY

Teratogenic effects


Nonteratogenic effects


NURSING MOTHERS



PEDIATRIC USE



TERAZOSIN HYDROCHLORIDE ADVERSE REACTIONS

Benign Prostatic Hyperplasia
Table 1PRECAUTIONS

**
Table 2

Hypertension
Table 3

**
Table 4

Post-marketing Experience

PRECAUTIONS

OVERDOSAGE



DOSAGE & ADMINISTRATION


Benign Prostatic Hyperplasia:
Initial Dose:


Subsequent Doses:
If terazosin administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen.
Use with Other Drugs:
Precautions

Hypertension:

Initial Dose:

Subsequent Doses:
. If terazosin administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen.
Use with other Drugs: (see above).

HOW SUPPLIED
























STORAGE AND HANDLING



INFORMATION FOR PATIENTS

PATIENT INFORMATION ABOUT
TERAZOSIN HYDROCHLORIDE
CAPSULES



When used to treat Hypertension or Benign Prostatic Hyperplasia (BPH)


What is hypertension (high blood pressure)?

Treatment options for hypertension

What TERAZOSIN HYDROCHLORIDE CAPSULES do to treat hypertension

What is BPH?

  • ●     a weak or interrupted stream when urinating
  • ●     a feeling that you can not empty your bladder completely
  • ●     a feeling of delay when you start to urinate
  • ●     a need to urinate often, especially at night, or
  • ●     a feeling that you must urinate right away
Treatment options for BPH

  •      Program of monitoring or "Watchful Waiting".

  •      Medication.There are different kinds of medication used to treat BPH. Your doctor has prescribed TERAZOSIN HYDROCHLORIDE CAPSULES for you. See "What TERAZOSIN HYDROCHLORIDE CAPSULES do to treat BPH" below.
  •      Surgery.Some patients may need surgery.

What TERAZOSIN HYDROCHLORIDE CAPSULES do to treat BPH

  • ●     TERAZOSIN HYDROCHLORIDE CAPSULES help relieve the symptoms of BPH. It does NOT change the size of the prostate, which may continue to grow. However, a larger prostate does not necessarily cause more or worse symptoms.
  • ●     If TERAZOSIN HYDROCHLORIDE CAPSULES are helping you, you should notice an effect on your particular symptoms in 2 to 4 weeks of starting to take the medication.
  • ●     Even though you take TERAZOSIN HYDROCHLORIDE CAPSULES and they may help you, TERAZOSIN HYDROCHLORIDE CAPSULES may not prevent the need for surgery in the future.
Other important facts about TERAZOSIN HYDROCHLORIDE CAPSULES for BPH
  • ●     You should see an effect on your symptoms in 2 to 4 week. So, you will need to continue seeing your doctor to check your progress regarding your BPH and to monitor your blood pressure in addition to your other regular check-ups.
  • ●     Your doctor has prescribed TERAZOSIN HYDROCHLORIDE CAPSULES for your BPH and not for prostate cancer. However, a man can have BPH and prostate cancer at the same time. Doctors usually recommend that men be checked for prostate cancer once a year when they turn 50 (or 40 if a family member has had prostate cancer). These checks should continue even if you are taking TERAZOSIN HYDROCHLORIDE CAPSULES. TERAZOSIN HYDROCHLORIDE CAPSULES are not a treatment for prostate cancer.
  • ●     About Prostate Specific Antigen (PSA). Your doctor may have done a blood test called PSA. Your doctor is aware that TERAZOSIN HYDROCHLORIDE CAPSULES do not affect PSA levels. You may want to ask your doctor more about this if you have had a PSA test done.
What you should know while taking TERAZOSIN HYDROCHLORIDE CAPSULES for hypertension or BPH
WARNINGS
TERAZOSIN HYDROCHLORIDE CAPSULES Can Cause A Sudden Drop In Blood Pressure After the VERY FIRST DOSE.


  • ●     You will start with a 1 mg dose of TERAZOSIN HYDROCHLORIDE CAPSULES. Then the dose will be increased as your body gets used to the effect of the medication.
  • ●     Other side effects you could have while taking TERAZOSIN HYDROCHLORIDE CAPSULES include drowsiness, blurred or hazy vision, nausea or "puffiness" of the feet or hands. Discuss any unexpected effects you notice with your doctor. Extremely rarely, TERAZOSIN HYDROCHLORIDE CAPSULES and similar medications have caused painful erection of the penis sustained for hours and unrelieved by sexual intercourse or masturbation. This condition is serious, and if untreated it can be followed by permanent inability to have an erection. If you have a prolonged abnormal erection, call your doctor or go to an emergency room as soon as possible.
How to take TERAZOSIN HYDROCHLORIDE CAPSULES



FOR MORE INFORMATION ABOUT TERAZOSIN HYDROCHLORIDE CAPSULES AND HYPERTENSION OR BPH, TALK WITH YOUR DOCTOR, NURSE, PHARMACIST OR OTHER HEALTH CARE PROVIDER.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Terazosin Hydrochloride

Terazosin Hydrochloride

Terazosin Hydrochloride

Terazosin Hydrochloride CAPSULE

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-808(NDC:59746-385)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
TERAZOSIN HYDROCHLORIDE TERAZOSIN 5 mg

Inactive Ingredients

Ingredient Name Strength
SILICON DIOXIDE
D&C RED NO. 28
D&C YELLOW NO. 10
GELATIN
MAGNESIUM STEARATE
lactose monohydrate
SODIUM LAURYL SULFATE
titanium dioxide

Product Characteristics

Color Size Imprint Code Shape
orange 16 mm TL385 CAPSULE

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-808-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075317 2011-11-10


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.